Patents Assigned to Antheia, Inc.
  • Methods of producing morphinan alkaloids and derivatives
    Patent number: 11884949
    Abstract: A method of producing promorphinan, morphinan, nal-opioid, and nor-opioid alkaloid products through the increased conversion of a promorphinan alkaloid to a morphinan alkaloid. The method comprises contacting the promorphinan alkaloid with at least one enzyme. Contacting the promorphinan alkaloid with the at least one enzyme converts the promorphinan alkaloid to a morphinan alkaloid.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: January 30, 2024
    Assignee: Antheia, Inc.
    Inventors: Christina D. Smolke, Isis Trenchard, Kristy M. Hawkins, Catherine Thodey
  • Compositions and methods for making (R)-reticuline and precursors thereof
    Patent number: 11613770
    Abstract: Methods that may be used for the manufacture of the chemical compound (R)-Reticuline and synthesis precursors thereof. Compositions useful for the synthesis (R)-Reticuline and synthesis precursors are also provided.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: March 28, 2023
    Assignee: ANTHEIA, INC.
    Inventors: Peter James Facchini, Scott Cameron Farrow, Guillaume Arthur Welch Beaudoin
  • Neopinone isomerase and methods of using
    Patent number: 11560578
    Abstract: Disclosed are methods for converting a first morphinan alkaloid compound into a second morphinan alkaloid compound in the presence of a neopinone isomerase enzyme under reaction conditions permitting the conversion of the first alkaloid compound into the second alkaloid compound. The first alkaloid compound can be neopinone or neomorphinone. The second alkaloid compound can be codeinone or morphinone. Related compositions are also disclosed.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 24, 2023
    Assignee: Antheia, Inc.
    Inventors: Peter J. Facchini, Xue Chen
  • Polynucleotides and polypeptides useful for making alkaloid compounds
    Patent number: 11479586
    Abstract: Polynucleotides and polypeptides useful in the manufacture of a class of chemical compounds known as alkaloids are provided. The polynucleotides and polypeptides may be used to synthesize alkaloids, including reticuline, thebaine and morphine, in vivo and in vitro. The polynucleotides further may be used to examine the presence of the polynucleotides in a cell or a cell extract, and to modulate expression thereof in living cells.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: October 25, 2022
    Assignee: Antheia, Inc.
    Inventors: Peter James Facchini, Joseph E. Tucker
  • Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids
    Patent number: 11427827
    Abstract: The present disclosure provides systems and methods for increasing production of an alkaloid product through the epimerization of a (S)-1-benzylisoquinoline alkaloid to a (R)-1-benyzlisoquinoline alkaloid via an engineered epimerase in an engineered host cell. A (S)-1-benzylisoquinoline alkaloid is contacted with said engineered epimerase. Contacting said (S)-1-benzylisoquinoline alkaloid with said engineered epimerase converts said (S)-1-benzylisoquinoline alkaloid to said (R)-1-benzylisoquinoline alkaloid.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: August 30, 2022
    Assignee: Antheia, Inc.
    Inventors: Christina D. Smolke, Derek H. Wells
  • Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
    Patent number: 11396668
    Abstract: A method of demethylizing an opioid to a nor-opioid is provided. The method comprises contacting an opioid with at least one enzyme. Contacting the opioid with the at least one enzyme converts the opioid to a nor-opioid. A method of converting a nor-opioid to a nal-opioid is provided. The method comprises contacting a nor-opioid with at least one enzyme. Contacting the nor-opioid with the at least one enzyme converts the nor-opioid to a nal-opioid.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: July 26, 2022
    Assignee: Antheia, Inc.
    Inventors: Christina D. Smolke, Catherine Thodey, Isis Trenchard
  • Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof
    Patent number: 11142780
    Abstract: Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (BIAs) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and/or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: October 12, 2021
    Assignee: Antheia, Inc.
    Inventors: Peter James Facchini, Xue Chen, Jeffrey C. Colbeck, Joseph Tucker
  • Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
    Patent number: 10738335
    Abstract: A method of demethylizing an opioid to a nor-opioid is provided. The method comprises contacting an opioid with at least one enzyme. Contacting the opioid with the at least one enzyme converts the opioid to a nor-opioid. A method of converting a nor-opioid to a nal-opioid is provided. The method comprises contacting a nor-opioid with at least one enzyme. Contacting the nor-opioid with the at least one enzyme converts the nor-opioid to a nal-opioid.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: August 11, 2020
    Assignee: Antheia, Inc.
    Inventors: Christina D. Smolke, Catherine Thodey, Isis Trenchard
  • Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids
    Patent number: 10544420
    Abstract: The present disclosure provides systems and methods for increasing production of an alkaloid product through the epimerization of a (S)-1-benzylisoquinoline alkaloid to a (R)-1-benyzlisoquinoline alkaloid via an engineered epimerase in an engineered host cell. A (S)-1-benzylisoquinoline alkaloid is contacted with said engineered epimerase. Contacting said (S)-1-benzylisoquinoline alkaloid with said engineered epimerase converts said (S)-1-benzylisoquinoline alkaloid to said (R)-1-benzylisoquinoline alkaloid.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: January 28, 2020
    Assignee: Antheia, Inc.
    Inventors: Christina D. Smolke, Derek H. Wells